Pure Biologics Chooses To Collaborate With Twist Bioscience To Increase Its Potential In The Field Of Phage Display Technology

Twist Bioscience Corporation, a company that helps customers achieve success by leveraging their high-quality synthetic DNA on its silicon platform, today announced a partnership with Pure Biologics, to accelerate the development of new antibody-based immuno-oncology drugs. “The unique methods and technical capabilities of Twist Bioscience enable the rapid creation of diverse synthetic libraries using modern and data-based randomization schemes. We expect that the potential of Twist Bioscience, combined with our activities in the field of immuno-oncology and scientific knowledge in the field of therapeutic bispecific antibodies and antibodies with fusion proteins, will allow us to accelerate the development of new drugs and create a basis for future research development, "said Dr. Filip Jelen, president of the company Pure Biologics SA. Pursuant to the Twist Biopharma agreement, the Twist Bioscience division will provide Pure Biologics with access to selected libraries of phage display of synthetic antibodies obtained exclusively from sequences occurring in the human body and additionally optimized by the latest methods using, among others, artificial intelligence and big data analytics. Some of the libraries in the portfolio are specially selected for selected classes of biological targets, as well as increasing the potential for the production of bispecific antibodies. As part of the collaboration, Twist Bioscience and Pure Biologics will work on the discovery, validation and optimization of new antibody candidates for selected biological targets in immuno-oncology applications. "We are delighted to be able to support Pure Biologics' immuno-oncology efforts with top-class bispecific antibodies identified and developed using our extraction and optimization engine," said Dr. Emily M. Leproust, CEO and co-founder of Twist Bioscience. 'The highly selective and potent action of bispecific antibodies, which bind to many biological targets, could lead to changes in cancer treatments in the future.'

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!